Please assess the completion status of the following clinical trial:

Trial Title: SRS (Stereotactic Radiosurgery) Plus Ipilimumab

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients must have histologically confirmed diagnosis of melanoma. The pathologic confirmation may be from another metastatic site or from metastatic brain or spine lesions.~2. Patients must have Stage IV melanoma, with newly identified brain or spine metastases.~3. Patients must have measurable lesion in the brain or spine that is \> 3 mm seen on magnetic resonance imaging (MRI) with contrast.~   NOTE: Contrasted pre-treatment MRI scan must be obtained ≤ 21 days prior to stereotactic radiosurgery treatment.~4. Karnofsky Performance Scale \>70%~5. Patients must have normal organ and marrow function as defined below:~   leukocytes \>3,000/mcL absolute neutrophil count \>1,500/mcL platelets \>100,000/mcL total bilirubin ≤2X institutional upper limit of normal AST(SGOT)/ALT(SGPT) \<2.5 X institutional upper limit of normal creatinine within normal institutional limits OR According to Johns Hopkins MRI policy~6. Women of child bearing potential (WOCBP) using a reliable form of contraception during the study treatment period and for up to 12 weeks following the last dose of study drug \[21\].~7. Men must agree to the use of male contraception during the study treatment period and for at least 12 weeks after the last dose of study drug.~8. Ability to understand and the willingness to sign written informed consent document(s).~Exclusion Criteria:~1. Prior whole brain radiation or conventional radiation to the spine at the site of new lesion.~2. Prior chemotherapy within 28 days of starting treatment.~3. Prior therapy with investigational drugs within 28 days or at least 5 half-lives (whichever is longer) before study administration.~4. Prior therapy with an anti-PD-1, anti-PD-L1, anti-PDL-2, or anti-CTLA-4 antibody.~5. Neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.~6. Known allergy to compounds of similar chemical or biologic composition to ipilimumab.~7. Pregnant or breastfeeding women.~8. Known history of Human Immunodeficiency Virus.~9. Active infection requiring therapy, positive tests for Hepatitis B surface antigen or Hepatitis C ribonucleic acid (RNA) \[11\].~10. Active autoimmune disease, history of autoimmune disease or history of syndrome that required systemic steroids or immunosuppressive medications. Exceptions include those with vitiligo or resolved childhood asthma/atopy. Subjects with asthma who require intermittent use of bronchodilators (such as albuterol) will not be excluded from this study \[11\].~11. Use of any vaccines against infectious diseases (e.g. varicella, influenza, etc.) up to 4 weeks (28 days) before receiving ipilimumab.~12. Prisoners or subjects who are compulsorily detained for treatment of either a psychiatric or physical (e.g. infectious disease) illness.~13. Patients with both brain and spine metastases will be excluded from the trial.~14. Patients who are allergic to MRI contrast agent or have contraindication for MRI.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Brain (Type: EXPERIMENTAL): A cohort of six (6) patients will be treated at Dosing Schedule 1. If the observed dose limiting toxicity (DLT) rate is less ≤33%, the dose cohort will be expended to a total of 15 patients. Brain and spine metastases will be evaluated as two separate cohorts.~If the first schedule produces DLTs in \>33% of patients, the Second Dosing schedule will be implemented. If the second dosing schedule produces DLTs in \>33% of patients, the Third Dosing schedule will be implemented.~After 6 patients were enrolled in a cohort, their safety and toxicity will be continuously monitored till 12 weeks (3 months) after the initial dose of Ipilimumab is given for evaluating dose-limiting toxicities.
- Spine (Type: EXPERIMENTAL): A cohort of six (6) patients will be treated at Dosing Schedule 1. If the observed dose limiting toxicity (DLT) rate is less ≤33%, the dose cohort will be expended to a total of 15 patients. Brain and spine metastases will be evaluated as two separate cohorts.~If the first schedule produces DLTs in \>33% of patients, the Second Dosing schedule will be implemented. If the second dosing schedule produces DLTs in \>33% of patients, the Third Dosing schedule will be implemented.~After 6 patients were enrolled in a cohort, their safety and toxicity will be continuously monitored till 12 weeks (3 months) after the initial dose of Ipilimumab is given for evaluating dose-limiting toxicities.

Based on this trial design, predict the completion outcome and termination type (if applicable).